TX-MARY-KAY-INC
8.5.2019 16:08:06 CEST | Business Wire | Press release
Mary Kay Inc., a global beauty company and leader in skin care innovation, continues its ongoing support of the beauty and scientific communities by participating in two global dermatological conferences this spring. Mary Kay attended the prestigious Reunión Anual de Dermatólogos Latinoamericanos (RADLA) May 4–7 in Buenos Aires, Argentina, where it presented findings related to the effects of pollution on skin health. The company will also sponsor the 77th Annual Meeting of the Society for Investigative Dermatology (SID) in Chicago, May 8–11, where it will reveal its latest research on how five fruit extracts known to contain vitamin C work to help skin appearance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005528/en/
During the 37th annual RADLA conference, leading skin care experts from around the world convened to explore various topics, including the impact of external environmental aggressors on skin health. Mary Kay presented research focused on skin concerns stemming from diesel exhaust particles (DEP) in the environment. Continued exposure to DEP increases free radicals in skin cells, which can ultimately impact premature signs of skin aging, like dark spots and dullness Fortunately, Mary Kay also presented findings on an antioxidant complex that can help delay the premature signs of aging related to the damaging effects of DEP. This breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
“Mary Kay scientists spent years researching the latest ingredient innovations to develop our newest skin care collection that defends against free radicals and helps delay the onset of premature skin aging from unavoidable environmental and lifestyle stressors such as car exhaust and air pollution,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc.
While attending SID this week, Mary Kay Associate Principal Scientist Tiffany Carle will present new data collected while analyzing the effects of a serum containing five botanical fruit extracts known to be rich in vitamin C on skin appearance. As part of this study, Mary Kay researchers treated artificial skin tissue with this serum and utilized a genomic approach to understand how the serum affected the skin. This genomic evaluation revealed involvement of four main classes of genes important for skin firmness. Furthermore, the study showcased that the serum treatment increased production of dermal matrix proteins collagen and laminin that support skin firmness. This study confirms how the serum works to help improve the appearance of skin laxity and texture.
Mary Kay’s Research and Development team is comprised of distinguished scientists who hold doctorates and other advanced degrees across multiple disciplines: skin biology, cell biology, chemistry, biochemistry and more. This team of scientists is dedicated to conducting ongoing breakthrough research and sharing impactful findings related to skin health with the scientific and beauty communities at large.
“Our Research & Development team is committed to developing the technology in our products so we can help improve skin health and provide women across the globe with the skin confidence they deserve,” said Dr. Gildea. “Participating in events like RADLA and SID allows us to learn and share relevant research so we can continue to deliver meaningful benefits and amazing products to consumers.”
Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio. Recently, the company announced the opening of a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, manufacture irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay FoundationSM , the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005528/en/
Contact:
Mary Kay Inc. Corporate Communications marykay.com/newsroom 972.687.5332 or media@mkcorp.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom